Chairman''s Speech - 68th Annual General Meeting

TTKH:SECL:SL:122:26 July 24, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai 400 001 Bandra East Mumbai 400 051 SCRIP CODE: 507747 SCRIP CODE: TTKHLTCARE Dear Sirs, Re : Chairman’s Speech – 68th Annual General Meeting of the Company – July 24, 2026 We are forwarding herewith a copy of the Chairman Speech delivered by Mr. K Shankaran, Director on behalf of the Chairman, at the 68th Annual General Meeting of our Company held today through Video Conferencing / Other Audio Visual Means (VC / OAVM). We request you to kindly take the above document on record. Thanking you Yours faithfully For TTK Healthcare Limited (GOWRY A JAISHANKAR) DGM – Legal & Company Secretary Encl. : a/a TTK HEALTHCARE LIMITED Regd. Office: No.6, Cathedral Road, Chennai 600 086 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com CHAIRMAN’S SPEECH [68th ANNUAL GENERAL MEETING – JULY 24, 2026] Ladies and Gentlemen, It gives me great pleasure to welcome you all to this 68th Annual General Meeting of your Company. TRIBUTE TO LATE MR. T T JAGANNATHAN At the outset, the Board places on record its deepest respect and appreciation to Mr T T Jagannathan, Former Chairman, who passed away on October 09, 2025. During his association with the Company nearly for four decades, he made invaluable contributions towards its growth and success. His vision, leadership and commitment will always be remembered with great respect and gratitude and the Board pays its heartfelt tribute to his enduring legacy. FINANCIAL YEAR 2025-26: The Annual Report for the year has already been circulated. I would like to touch upon the salient features of the Company’s performance during the year under review. Financial Highlights:  Revenue from Operations amounted to Rs.857.28 crores as against the previous year’s figure of Rs.801.49 crores, with a growth of around 7%.  The Pre-tax Profit after Exceptional Items stood at Rs.82.56 crores [Previous Year: Rs.108.33 crores]. The Exceptional Items for the year amounted to negative of Rs.407.45 lakhs [Previous Year: Rs.1,390.66 lakhs]. The drop in profit was mainly on account of lower profit reported by Protective Devices Division due to loss of Institutional / Tender business particularly from USAID.  Earnings per Share (EPS) was Rs.46.48 (Previous Year: Rs.57.79).  Your Company carries a free Cash Balance of around Rs.900 crores, as at March 31, 2026. SALE OF EVA AND GOOD HOME BRANDS: EVA and Good Home, an integral part of our Consumer Products portfolio are earning the trust of consumers for many years. Sustained efforts of the Company and huge investments on these two brands have brought the combined turnover of Rs.148 crores for the FY 2025-26. Page 1 As part of the strategic direction for Consumer Products Division and also considering the current market scenario, the Board of Directors thought it would be a good idea to divest these brands. Accordingly, definitive agreements have been entered into with M/s Wipro Enterprises Private Limited for sale of these two brands at a consideration of Rs.256 crores plus applicable GST, with the closing of the transaction contemplated thereunder being subject to the fulfilment of the ‘conditions precedent’ that are customary in such transactions. Your Directors believe Wipro is well positioned to take these brands to the next stage of growth supported by its strong FMCG capabilities and proven track record of nurturing the acquired brands. BUSINESSWISE PERFORMANCE: Let me now provide a quick brief on the performance of the various businesses of the Company during 2025-26 and also the plans for the year 2026-27. (1) Consumer Products Business (CPD) reported a static performance. The year 2025–26 was challenging for Woodward’s Gripe Water (WGW), with volume declines, particularly in Southern markets. However, e-Commerce and Modern Trade delivered strong growth though on a lower base. To strengthen brand momentum, the Company nationally launched the “I Am Woodward’s Baby” campaign, reinforcing product safety and its legacy of trust, supported by regional activations in Tamil Nadu and the Western markets. The launch of Woodward’s Tummy Roll-On on e-Commerce platforms also marked the brand’s entry into the “Care” segment, strengthening its positioning as a Tummy Care Expert. For 2026–27, the strategy focuses on enhancing brand relevance and driving earlier adoption among new-age parents through: (i) a new communication platform educating parents on infant tummy care and the role of gripe water, on the basis of the insights gathered through a national survey; (ii) expansion of the “Care” portfolio with the proposed launch of Tummy Tonic in Tamil Nadu, supported by media campaigns and paediatrician engagement; and (iii) wider distribution of Tummy Roll-On through quick-commerce and specialty pharmacy channels. These initiatives support the Company’s vision of evolving Woodward’s from a single-product brand into a comprehensive Tummy Care expert while preserving its long-standing legacy of trust. Skore delivered resilient performance during the year under review, achieving 6% value growth while maintaining volumes despite challenges in traditional trade. E-commerce remained a key growth driver, delivering strong performance. Page 2 For 2026–27, the focus will be on accelerating growth through premium product launches across traditional trade and e-commerce channels, supported by sustained brand-building campaigns to enhance consumer awareness and brand salience. (2) Animal Welfare Business (AWD) reported a revenue growth of around 12%, driven by a stronger second-half performance. While Bovianim, Gallus and Aquanim recorded a robust growth, Companim grew only by 5% amid market-related challenges. For 2026–27, the Division will focus on strengthening its flagship brands through farm programmes and KOL engagement, accelerating growth by bifurcating the Bovianim business, revitalising the Companim portfolio, expanding e-commerce, quick-commerce and retail channels, and driving incremental revenue through targeted new product launches. (3) Medical Devices Business: Heart Valve Division reported a revenue growth of around 2%. While supplies of CardiaMed Bi- Leaflet Valves were impacted by the Russia–Ukraine conflict, limited imports from the Russian manufacturer helped address availability. Considering this, the Division will focus on increasing volumes of TTK Chitra Heart Valves. The single-centric pilot study of the improved TC2 TTK Chitra Titanium Heart Valve has been completed, with encouraging three-year follow-up results. Subject to funding and regulatory approvals, the Company plans to commence pivotal studies involving around 400 patients. Ortho Division reported a strong revenue growth of 27%, supported by robust performance across key markets and expansion into new regions. The pilot launch of the Citius Fixed Bearing Knee Implant received an encouraging response, while TiN-coated implants and the Hip Implants portfolio delivered healthy growth. For 2026–27, the Division will focus on the nationwide rollout of Citius, expansion of the field force, launch of the Revision Hip Implant System and TiN-Coated Fortius Fixed Bearing Knee Implants, enhancement of manufacturing capacity and automation, and development of new products, including Ankle and Unicondylar Knee Replacement Implants. (4) Protective Devices Business reported a revenue growth of around 5%. Despite initial challenges arising from the cessation of USAID business and the absence of a long-term agreement with UNFPA, the Division recovered through new customer additions and ended the year on a positive note. The Company retained its WHO-UNFPA pre-qualified supplier status, expanded its customer base through strong quality standards, initiated product registrations in multiple countries, and continued to pursue export opportunities and sustainability initiatives. Page [Showing first 8,000 characters — download PDF for full document]